Chairman, CEO & President
Doug is a technology executive and entrepreneur with 30 years experience ranging from start-ups to large publicly traded companies. He served as Chairman and CEO of Ahura Scientific Corporation from 2003-2010. There he guided this manufacturer of handheld spectroscopic instruments from start-up to sale. The company was acquired by Thermo Fisher Scientific for approximately $190M. Prior to this, he was CEO of PanAmSat, the world’s largest public satellite services company with annual revenues in excess of $800 million. Previously, he served as President and CEO of Easel Corporation, taking it from its early stage venture capital days through a successful IPO and four years beyond. Doug holds a BS in Engineering from Cornell University and an MBA from Stanford University. Doug currently serves as a Trustee of Olin College of Engineering, Needham, MA where he is also Chairman of the Investment Committee. He was a past recipient of the Entrepreneur of the Year award and the SBANE New Englander award for innovation and achievement. He served previously as Director of Advanced Visual Systems, ServiceSoft Corp, Rosh Intelligent Systems and others.
Chief Scientific Officer
Ted is the company founder and a Professor in the Department of Microbiology and Immunology at Cornell University. He has more than 20 years experience in cell and molecular biology, and has worked extensively with Tetrahymena and other ciliates. Ted received his PhD in Cell and Developmental Biology from the State University of New York at Stony Brook and did his postdoctoral training at Yale University. He spent more than a decade at the University of Georgia where he began efforts to develop Tetrahymena as an alternative expression host for recombinant proteins. He is Director of the Graduate Program in Immunology at Cornell and is a member of the board of reviewers for the Journal of Eukaryotic Microbiology.
Chief Financial Officer
Kevin is TetraGenetics’ Chief Financial Officer, and has been a senior financial executive of five successive venture-financed companies that he helped grow and lead to successful exit or IPO. He was the CFO at Ahura Scientific, a manufacturer of handheld spectroscopy instruments, which grew from $1M to $70M in revenues and was sold to Thermo Fisher Scientific for approximately $190M. Prior to Ahura, Kevin was CFO at Innoveda, a software company created from a leveraged buyout that grew from $50M to $100M in revenues, went public, and ultimately sold to Mentor Graphics. He was also the Vice President of Finance at Easel Corporation, a software company that grew rapidly and had a successful IPO. Kevin has a broad operating and financial background as well as extensive experience with mergers and acquisitions.
Vice President, Research
Paul is TetraGenetics’ Vice President, Research. Before joining the TetraGenetics team he was involved in expression platform development at New England Biolabs for seven years culminating in the release of the commercially available K. lactis yeast expression kit. Currently, he oversees TetraGenetics’ drug discovery pipeline as well as projects for both corporate and government clients. He obtained his BSc (Hons) from the University of Sydney and his PhD from the Biochemistry Department at the University of Illinois.
Director of External Alliances
Yelena is TetraGenetics’ Director of External Alliances. In addition to her role of establishing strategic partnerships within the pharmaceutical industry and collaborations with leading academics Yelena maintains a senior scientist role in the company. Yelena was instrumental in developing the TetraExpress™ platform that has allowed it to establish itself as the premium expression technology for the production of recombinant human ion channels. Yelena obtained her BS and MS from Yerevan State University and her PhD from Cornell University.